‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

por Pallis, A G, Voutsina, A, Kalikaki, Ar, Souglakos, J, Briasoulis, E, Murray, S, Koutsopoulos, A, Tripaki, M, Stathopoulos, E, Mavroudis, D, Georgoulias, V
Publicado 2007